Mr. Dean Sullivan:

The HSE is involved in price negotiations on all of the drugs. That is part of the arrangement. Cost-effectiveness is a combination of those two dimensions. There are two ways a drug can become more cost-effective - either more evidence will emerge as to the impact it is having on patient outcomes and-or the pharmaceutical company can reduce the price. We have left both of those options to the relevant pharmaceutical company in this case that if additional evidence can be brought forward about effectiveness and-or a lower cost per patient we would consider this again.